Browsing by Publisher "European Respiratory Society"
Now showing 1 - 12 of 12
Results Per Page
Sort Options
Item International European respiratory society/American thoracic society guidelines on severe asthma(European Respiratory Society, 2014) Bousquet J.; Khaltaev N.; Cruz A.; Yorgancioglu A.; Chuchalin A.[No abstract available]Item AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation(European Respiratory Society, 2016) Bousquet J.; Barbara C.; Bateman E.; Bel E.; Bewick M.; Chavannes N.H.; Cruz A.A.; Haahtela T.; Hellings P.W.; Khaltaev N.; Carlsen K.L.; Muraro A.; Cordeiro C.R.; Rosado-Pinto J.; Samolinski B.; Strandberg T.; Valiulis A.; Yorgancioglu A.; Zuberbier T.; Adcock I.; Addis A.; Agache I.; Agusti A.; Alonso A.; Annesi Maesano I.; Anto J.M.; Bachert C.; Baena-Cagnani C.; Bai C.; Baigenzhin A.; Barnes P.J.; Beck L.; Bedbrook A.; Benezet O.; Bennoor K.S.; Benson M.; Bernabeu-Wittel M.; Bindslev Jensen C.; Blain H.; Blasi F.; Bonini M.; Bonini S.; Boulet L.P.; Bourdin A.; Bourret R.; Bousquet P.J.; Brightling C.E.; Briggs A.; Brozek J.; Buhl R.; Bush A.; Caimmi D.; Calderon M.; Calverley P.; Camargos P.; Camuzat T.; Canonica G.W.; Carlsen K.H.; Casale T.B.; Cazzola M.; Cepeda Sarabia A.M.; Cesario A.; Chen Y.Z.; Chkhartishvili E.; Chiron R.; Chuchalin A.; Chung K.F.; Cox L.; Crooks G.; Crooks M.G.; Custovic A.; Dahl R.; Dahlen S.E.; De Blay F.; Dedeu T.; Deleanu D.; Demoly P.; Devillier P.; Didier A.; Dinh Xuan A.T.; Djukanovic R.; Dokic D.; Douagui H.; Dubakiene R.; Eglin S.; Elliot F.; Emuzyte R.; Fabbri L.; Fink-Wagner A.; Fletcher M.; Fokkens W.J.; Fonseca J.; Franco A.; Frith P.; Furber A.; Gaga M.; Gamkrelidze A.; Garcia Aymerich J.; González-Díaz S.; Gouzi F.; Garcés J.; Guzmán M.A.; Harrison D.; Hayot M.; Heaney L.; Heinrich J.; Hooper J.; Humbert M.; Hyland M.; Iaccarino G.; Jakovenko D.; Jardim J.; Jeandel C.; Jenkins C.; Johnston S.L.; Jonquet O.; Joos G.; Jung K.S.; Kalayci O.; Karunanithi S.; Keil T.; Kolek V.; Kowalski M.; Kull I.; Kuna P.; Kvedariene V.; Le L.T.; Louis R.; MacNee W.; Mair A.; Manning P.; Manuel Keenoy M.E.; Majer I.; Masjedi M.R.; Melén E.; Melo Gomes E.; Menzies-Gow A.; Mercier G.; Mercier J.; Michel J.P.; Miculinic N.; Mihaltan F.; Milenkovic B.; Molimard M.; Momas I.; Montilla-Santana A.; Morais Almeida M.; Morgan M.; N'Diaye M.; Nafti S.; Nekam; Neou A.; Nicod L.; O'Hehir R.; Ohta K.; Paggiaro P.; Palkonen S.; Palmer S.; Papadopoulos N.G.; Papi A.; Passalacqua G.; Pavord I.; Pedersen S.; Pigearias B.; Plavec D.; Postma D.S.; Price D.; Rabe K.F.; Radier Pontal F.; Redon J.; Rennard S.; Roberts J.; Robine J.M.; Roca J.; Roche N.; Rodenas F.; Roggeri A.; Rolland C.; Ryan D.; Sanchez-Borges M.; Schünemann H.J.; Sheikh A.; Shields M.; Siafakas N.; Sibille Y.; Similowski T.; Small I.; Sola-Morales O.; Sooronbaev T.; Stelmach R.; Sterk P.J.; Stiris T.; Sud P.; Tellier V.; To T.; Todo Bom A.; Triggiani M.; Valenta R.; Valero A.L.; Valovirta E.; Vandenplas O.; Van Ganse E.; Vasankari T.; Vestbo J.; Vezzani G.; Viegi G.; Visier L.; Vogelmeier C.; Vontetsianos T.; Wagstaff R.; Wallaert B.; Wahn U.; Whalley B.; Wickman M.; Williams D.; Wilson N.; Yawn B.P.; Yiallouros P.; Yusuf O.; Zar H.J.; Zhong N.; Zidarn M.[No abstract available]Item Protocol for the earco registry: A pan-european observational study in patients with α1-antitrypsin deficiency(European Respiratory Society, 2020) Greulich T.; Altraja A.; Barrecheguren M.; Bals R.; Chlumsky J.; Chorostowska-Wynimko J.; Clarenbach C.; Corda L.; Corsico A.G.; Ferrarotti I.; Esquinas C.; Gouder C.; Hećimović A.; Ilic A.; Ivanov Y.; Janciauskiene S.; Janssens W.; Kohler M.; Krams A.; Lara B.; Mahadeva R.; McElvaney G.; Mornex J.-F.; O’hara K.; Parr D.; Piitulainen E.; Schmid-Scherzer K.; Seersholm N.; Stockley R.A.; Stolk J.; Sucena M.; Tanash H.; Turner A.; Ulmeanu R.; Wilkens M.; Yorgancioğlu A.; Zaharie A.; Miravitlles M.Rationale and objectives: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed to bring together researchers from European countries and to create a standardised database for the follow-up of patients with AATD. Study design and population: The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patients with AATD. Data will be collected prospectively without interference/modification of patient’s management by the study team. The major inclusion criterion is diagnosed severe AATD, defined by an AAT serum level <11 µM (50 mg·dL−1 ) and/or a proteinase inhibitor genotype ZZ, SZ or compound heterozygotes or homozygotes of other rare deficient variants. Assessments at baseline and during the yearly follow-up visits include lung function testing (spirometry, body plethysmography and diffusing capacity of the lung), exercise capacity, blood tests and questionnaires (symptoms, quality of life and physical activity). To ensure correct data collection, there will be designated investigator staff to document the data in the case report form. All data will be reviewed by the EARCO database manager. Summary: The EARCO Registry aims to understand the natural history and prognosis of AATD better with the goal to create and validate prognostic tools to support medical decision-making. © ERS 2020.Item A global respiratory perspective on the COVID-19 pandemic: Commentary and action proposals(European Respiratory Society, 2020) To T.; Viegi G.; Cruz A.; Taborda-Barata L.; Asher I.; Behera D.; Bennoor K.; Boulet L.-P.; Bousquet J.; Camargos P.; Conceiçao C.; Diaz S.G.; El-Sony A.; Erhola M.; Gaga M.; Halpin D.; Harding L.; Maghlakelidze T.; Masjedi M.R.; Mohammad Y.; Nunes E.; Pigearias B.; Sooronbaev T.; Stelmach R.; Tsiligianni I.; Lan L.T.T.; Valiulis A.; Wang C.; Williams S.; Yorgancioglu A.[No abstract available]Item European respiratory society clinical practice guidelines for the diagnosis of asthma in children aged(European Respiratory Society, 2021) Gaillard E.A.; Kuehni C.E.; Turner S.; Goutaki M.; Holden K.A.; de Jong C.C.M.; Lex C.; Lo D.K.H.; Lucas J.S.; Midulla F.; Mozun R.; Piacentini G.; Rigau D.; Rottier B.; Thomas M.; Tonia T.; Usemann J.; Yilmaz O.; Zacharasiewicz A.; Moeller A.Diagnosing asthma in children represents an important clinical challenge. There is no single gold standard test to confirm the diagnosis. Consequently, both over-, and under-diagnosis of asthma are frequent in children. A Task Force (TF) supported by the European Respiratory Society has developed these evidence-based clinical practice guidelines for the diagnosis of asthma in children aged 5 to 16 years using nine PICO (Population, Intervention, Comparator and Outcome) questions. The TF conducted systematic literature searches for all PICO questions and screened the outputs from these, including relevant full text articles. All TF members approved the final decision for inclusion of research papers. The TF assessed the quality of the evidence using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The TF then developed a diagnostic algorithm based on the critical appraisal of the PICO questions, preferences expressed by lay members and test availability. Proposed cut-offs were determined based on the best available evidence. The TF formulated recommendations using the GRADE Evidence to Decision framework. Based on the critical appraisal of the evidence and the Evidence to Decision Framework the TF recommends spirometry, bronchodilator reversibility testing and FeNO as first line diagnostic tests in children under investigation for asthma. The TF recommends against diagnosing asthma in children based on clinical history alone or following a single abnormal objective test. Finally, this guideline also proposes a set of research priorities to improve asthma diagnosis in children in the future. © 2021 European Respiratory Society. All rights reserved.Item Clean air for healthy lungs - An urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines(European Respiratory Society, 2021) Andersen Z.J.; Gehring U.; De Matteis S.; Melen E.; Vicedo-Cabrera A.M.; Katsouyanni K.; Yorgancioglu A.; Ulrik C.S.; Medina S.; Hansen K.; Powell P.; Ward B.; Hoffmann B.[No abstract available]Item Air pollution and COVID-19: Clearing the air and charting a post-pandemic course: A joint workshop report of ERS, ISEE, HEI and WHO(European Respiratory Society, 2021) Andersen Z.J.; Hoffmann B.; Morawska L.; Adams M.; Furman E.; Yorgancioglu A.; Greenbaum D.; Neira M.; Brunekreef B.; Forastiere F.; Rice M.B.; Wakenhut F.; Coleen E.; Boogaard H.; Gehring U.; Melén E.; Ward B.; de Matteis S.[No abstract available]Item Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes(European Respiratory Society, 2022) Reddel H.K.; Bacharier L.B.; Bateman E.D.; Brightling C.E.; Brusselle G.G.; Buhl R.; Cruz A.A.; Duijts L.; Drazen J.M.; FitzGerald J.M.; Fleming L.J.; Inoue H.; Ko F.W.; Krishnan J.A.; Levy M.L.; Lin J.; Mortimer K.; Pitrez P.M.; Sheikh A.; Yorgancioglu A.A.; Boulet L.-P.The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g. medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β2agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by ≥60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, “MART”) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting β2-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes. © 2022 by the American Thoracic Society, which grants unconditional and unlimited licenses to the EuropeanItem Type 2 inflammation in asthma and other airway diseases(European Respiratory Society, 2022) Maspero J.; Adir Y.; Al-Ahmad M.; Celis-Preciado C.A.; Colodenco F.D.; Giavina-Bianchi P.; Lababidi H.; Ledanois O.; Mahoub B.; Perng D.-W.; Vazquez J.C.; Yorgancioglu A.Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic COPD and allergic rhinitis are a global health concern. Despite the coexistence of these diseases and their common pathophysiology, they are often managed independently, resulting in poor asthma control, continued symptoms and poor quality of life. Understanding disease pathophysiology is important for best treatment practice, reduced disease burden and improved patient outcomes. The pathophysiology of type 2 inflammation is driven by both the innate immune system triggered by pollutants, viral or fungal infections involving type 2 innate lymphoid cells (ILC2) and the adaptive immune system, triggered by contact with an allergen involving type 2 T-helper (Th2) cells. Both ILC2 and Th2 cells produce the type-2 cytokines (interleukin (IL)-4, IL-5 and IL-13), each with several roles in the inflammation cascade. IL-4 and IL-13 cause B-cell class switching and IgE production, release of pro-inflammatory mediators, barrier disruption and tissue remodelling. In addition, IL-13 causes goblet-cell hyperplasia and mucus production. All three interleukins are involved in trafficking eosinophils to tissues, producing clinical symptoms characteristic of chronic inflammatory airway diseases. Asthma is a heterogenous disease; therefore, identification of biomarkers and early targeted treatment is critical for patients inadequately managed by inhaled corticosteroids and long-acting β-agonists alone. The Global Initiative for Asthma guidelines recommend add-on biological (anti IgE, IL-5/5R, IL-4R) treatments for those not responding to standard of care. Targeted therapies, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab, were developed on current understanding of the pathophysiology of type 2 inflammation. These therapies offer hope for improved management of type 2 inflammatory airway diseases. © The authors 2022.Item Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening(European Respiratory Society, 2023) Ward B.; Vašáková M.K.; Cordeiro C.R.; Yorgancioğlu A.; Chorostowska-Wynimko J.; Blum T.G.; Kauczor H.-U.; Samarzija M.; Henschke C.; Wheelock C.; Grigg J.; Andersen Z.J.; Koblížek V.; Májek O.; Odemyr M.; Powell P.; Seijo L.M.[No abstract available]Item Climate change and respiratory health: a European Respiratory Society position statement(European Respiratory Society, 2023) Vicedo-Cabrera A.M.; Melén E.; Forastiere F.; Gehring U.; Katsouyanni K.; Yorgancioglu A.; Ulrik C.S.; Hansen K.; Powell P.; Ward B.; Hoffmann B.; Andersen Z.J.[No abstract available]Item Ensuring availability of respiratory medicines in times of European drug shortages(European Respiratory Society, 2024) van Boven J.F.M.; Yorgancioglu A.; Roche N.; Usmani O.S.[No abstract available]